Literature DB >> 24514095

Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006.

Arnau Domenech1, Jose M Tirado-Vélez, Asunción Fenoll, Carmen Ardanuy, Jose Yuste, Josefina Liñares, Adela G de la Campa.   

Abstract

In Spain, rates of ciprofloxacin resistance in pneumococci were low during the last decade (2.6% in 2002 and 2.3% in 2006). In 2012, the rate remained at 2.3%, equivalent to 83 of 3,621 isolates. Of the 83 resistant isolates, 15 showed a low level (MIC of 4 to 8 μg/ml) and 68 a high level (MIC of 16 to 128 μg/ml) of ciprofloxacin resistance. Thirteen low-level-resistant isolates had single changes in ParC, one had a single ParE change, and one did not present any mutations. High-level-resistant isolates had GyrA changes plus additional ParC and/or ParE changes: 51, 15, and 2 isolates had 2, 3, or 4 mutations, respectively. Although 24 different serotypes were observed, 6 serotypes accounted for 51.8% of ciprofloxacin-resistant isolates: 8 (14.5%), 19A (10.8%), 11A (7.2%), 23A (7.2%), 15A (6.0%), and 6B (6.0%). A decrease in pneumococcal 7-valent conjugate vaccine (PCV7) serotypes was observed from 2006 (35.7%) to 2012 (16.9%), especially of serotype 14 (from 16.3% to 2.4%; P<0.001). In comparison with findings in 2006, multidrug resistance was greater in 2012 (P=0.296), mainly due to the increased presence and/or emergence of clonal complexes associated with non-PCV7 serotypes: CC63 expressing serotypes 8, 15A, and 19A; CC320 (with serotype 19A); and CC42 (with serotype 23A). Although rates of ciprofloxacin resistance remained low and stable throughout the last decade, changes in serotype and genotype distributions were observed in 2012, notably the expansion of a preexisting multidrug-resistant clone, CC63, and the emergence of the CC156 clone expressing serotype 11A.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24514095      PMCID: PMC4023713          DOI: 10.1128/AAC.02669-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network.

Authors:  L McGee; L McDougal; J Zhou; B G Spratt; F C Tenover; R George; R Hakenbeck; W Hryniewicz; J C Lefévre; A Tomasz; K P Klugman
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.

Authors:  E Fernandez-Moreira; D Balas; I Gonzalez; A G de la Campa
Journal:  Microb Drug Resist       Date:  2000       Impact factor: 3.431

4.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  L M Weigel; G J Anderson; R R Facklam; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods.

Authors:  Arnau Domenech; Carmen Ardanuy; Anais Tercero; Dolors García-Somoza; Salud Santos; Josefina Liñares
Journal:  J Antimicrob Chemother       Date:  2013-12-08       Impact factor: 5.790

8.  Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.

Authors:  Serge Houssaye; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

10.  High-efficiency generation of antibiotic-resistant strains of Streptococcus pneumoniae by PCR and transformation.

Authors:  Antonio J Martín-Galiano; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  12 in total

1.  Differences in antibiotic-induced oxidative stress responses between laboratory and clinical isolates of Streptococcus pneumoniae.

Authors:  Bédis Dridi; Andréanne Lupien; Michel G Bergeron; Philippe Leprohon; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

2.  Reactive Oxygen Species Production Is a Major Factor Directing the Postantibiotic Effect of Fluoroquinolones in Streptococcus pneumoniae.

Authors:  M T García; M V Valenzuela; M J Ferrándiz; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Correlation between gyrA and CmeR Box Polymorphism and Fluoroquinolone Resistance in Campylobacter jejuni Isolates in China.

Authors:  Tengfei Zhang; Yiluo Cheng; Qingping Luo; Qin Lu; Jun Dong; Rongrong Zhang; Guoyuan Wen; Honglin Wang; Ling Luo; Hongcai Wang; Guoping Liu; Huabin Shao
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.

Authors:  M J Ferrándiz; A J Martín-Galiano; C Arnanz; T Zimmerman; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

Review 5.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

6.  Emerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitro.

Authors:  Mirian Domenech; Diana Damián; Carmen Ardanuy; Josefina Liñares; Asunción Fenoll; Ernesto García
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

7.  Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to Streptococcus pseudopneumoniae.

Authors:  María Alvarado; Antonio J Martín-Galiano; María J Ferrándiz; Ángel Zaballos; Adela G de la Campa
Journal:  Front Microbiol       Date:  2017-10-26       Impact factor: 5.640

8.  [Antibiotic susceptibility of Staphylococcus aureus and Streptococcus pneumoniae in healthy carrier individuals in primary care in Barcelona area].

Authors:  Carles Llor; Albert Boada; Mariona Pons-Vigués; Elisabet Grenzner; Rosa Juvé; Jesús Almeda
Journal:  Aten Primaria       Date:  2017-04-14       Impact factor: 1.137

9.  Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.

Authors:  Jose Manuel Tirado-Vélez; David Carreño; David Sevillano; Luis Alou; José Yuste; Adela G de la Campa
Journal:  Antibiotics (Basel)       Date:  2021-05-13

10.  Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.

Authors:  Myriam V Valenzuela; Mirian Domenech; Patricia Mateos-Martínez; Fernando González-Camacho; Adela G de la Campa; Maria Teresa García
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.